SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London's Andrew Scott they're looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It's part of their collaboration with Winclove Probiotics which is well ahead of schedule. Ashman adds that their work with partner Croda to develop an active skincare ingredient is also making good progress.
viewSkinBioTherapeutics PLC
SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement
Quick facts: SkinBioTherapeutics PLC
Price: 16.375 GBX
AIM:SBTX
Market: AIM
Market Cap: £25.53 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
SkinBioTherapeutics continues workings on its partnerships
Most read
Finance
Elon Musk overtakes Bill Gates in billionaires list as Tesla stock continues...
4 days, 20 hours ago
Finance
Lloyds, Barclays and other bank stocks hit by grim economic forecasts in...
3 days, 16 hours ago
Industry & services
Falcon Oil & Gas still has lots of potential at Beetaloo say brokers
3 days, 18 hours ago
Mining
Jefferies forecasts multi-year copper deficits, a surge in prices and plenty...
4 days, 18 hours ago
